Liver and Bile

Clin Gastroenterol Hepatol. 2024;22(5):1037–47.e9

Kjaergaard M, Prier Lindvig K, Holtz Thorhauge K, Johansen S, Kragh Hansen J, Andersen P, Dalby Hansen C, Lindholm Schnefeld H, Tholstrup Bech K, Torp N, Israelsen M, Detlefsen S, Graupera I, Gines P, Krag A, Thiele M

Screening for fibrosis promotes lifestyle changes: A prospective cohort study in 4796 individuals


Background and aims: Early detection of liver fibrosis is believed to promote lifestyle changes. The authors evaluated self-reported changes in alcohol intake, diet, exercise, and weight after participating in a screening study for liver fibrosis.
Methods: They conducted a prospective screening study of individuals at risk of alcohol-related liver disease (ALD) or metabolic dysfunction-associated steatotic liver disease (MASLD). Lifestyle advice was provided to all participants and lifestyle changes were evaluated by questionnaires after 1 week and 6 months, with re-examination of a subgroup after 2 years.
Results: A total of 1850 at risk of ALD and 2946 at risk of MASLD were included, of whom 383 (8%) were screening-positive (transient elastography ≥ 8 kPa). A total of 84% replied to the 6-month questionnaire. In ALD participants, excessive drinking decreased from 46% to 32% after 6 months. Only 15% reported increased drinking, without differences between screening-positive and -negative individuals (p = 0.698). In high-risk drinkers, a positive screening test predicted abstinence or decreased alcohol use after 6 months (odds ratio [OR] = 2.45; 95% confidence interval [CI]: 1.32–4.57; p = 0.005). After 2 years, excessive drinking decreased from 52% to 41% in a subgroup of 752 individuals and a positive screening test predicted abstinence or decreased alcohol use after 2 years (OR = 1.84; 95% CI: 1.09–3.11, p = 0.023). MASLD participants showed similar improvements: 35% improved their diet, 22% exercised more, and 13% reported a weight loss ≥ 5% after 6 months.

Conclusions: Screening for liver fibrosis is associated with sustained improvements in alcohol consumption, diet, weight, and exercise in at-risk alcohol-related liver disease and metabolic dysfunction-associated steatotic liver disease. The changes are most pronounced in screening-positive participants but not limited to this group.

A. Krag, FLASH Liver Research Centre, Odense University Hospital, Odense, Denmark, E-Mail: aleksander.krag@rsyd.dk

DOI: 10.1016/j.cgh.2023.12.018

Back to overview

this could be of interest:

An open-label randomised-controlled trial of azathioprine vs. mycophenolate mofetil for the induction of remission in treatment-naive autoimmune hepatitis

J Hepatol. 2024;80(4):576–85

Association of hepatitis delta virus with liver morbidity and mortality: A systematic literature review and meta-analysis

Hepatology. 2024;79(5):1129–40

More articles on the topic